Vemurafenib improves survival in BRAF mutant melanoma

File:Melanoma.jpg

Pretty sure you already know this by now, considering the results of recent phase 1 and phase 3 trials. Here, the results of a phase 2 trial are presented in the New England Journal of Medicine. 

This article has got a great figure 1 – worth presenting if you’re looking to summarise the impact vemurafenib will have on melanoma treatment. Overall survival duration was almost 16 months – and importantly, cutaneous SCCs occurred in just over a quarter of patients.

Read it here.

 

image | NCI

source | NEJM

Advertisements

One thought on “Vemurafenib improves survival in BRAF mutant melanoma

  1. Pingback: medjuice | review | immunotherapy for melanoma

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s